Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03387020 · ClinicalTrials.gov registry record · Phase 1
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
A Phase 1 study of Malignant Glioma and Recurrent Medulloblastoma, sponsored by Pediatric Brain Tumor Consortium.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
- 12
- Study locations
NCT03387020 is a Phase 1 study of Malignant Glioma and Recurrent Medulloblastoma that has completed, run by Pediatric Brain Tumor Consortium. The registered enrollment target is 22 participants, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (76% lower). The trial reports 12 study locations across 10 states.
The verdict
NCT03387020, a Phase 1 study of Malignant Glioma and Recurrent Medulloblastoma, has completed, sponsored by Pediatric Brain Tumor Consortium.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
- 12
- Study locations
Study Summary
This phase I trial studies the side effects and best dose of ribociclib and everolimus and to see how well they work in treating patients with malignant brain tumors that have come back or do not respond to treatment. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ribociclib and everolimus may work better at treating malignant brain tumors.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Everolimus
- DRUG Ribociclib
- OTHER Pharmacological Study
Study Locations (12)
California
- Children's Hospital Los Angeles - Los Angeles
- Lucile Packard Children Hospital Stanford University - Palo Alto
Tennessee
- Pediatric Brain Tumor Consortium - Memphis
- St. Jude Children Research Hospital - Memphis
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Atlanta
Maryland
- National Cancer Institute Pediatric Oncology Branch - Bethesda
New York
- Memorial Sloan Kettering Cancer Center - New York
Ohio
- Cincinnati Children Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2018-01-13 |
| Est. Completion | 2020-04-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03387020
The ClinicalTrials.gov registry entry for NCT03387020 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 91-participant average among 40 other Malignant Glioma trials with a reported enrollment target (76% lower). The listed sponsor is Pediatric Brain Tumor Consortium, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Malignant Glioma appearing as the primary indexed condition, and to 4 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT03387020 reports 12 study locations spanning 10 distinct geographic areas - top geographies include California, Tennessee, Colorado.
Frequently Asked Questions
What is clinical trial NCT03387020 about?
NCT03387020 is a clinical study titled "Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors". This phase I trial studies the side effects and best dose of ribociclib and everolimus and to see how well they work in treating patients with malignant brain tumors that have come back or do not respond to treatment. Ribociclib may stop the growth of tumor cells by blocking some of the enzymes need...
What is the current status of trial NCT03387020?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2018-01-13. Estimated completion is 2020-04-01.
What conditions does trial NCT03387020 study?
This clinical trial studies the following conditions: Malignant Glioma, Recurrent Medulloblastoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Childhood Ependymoma, Refractory Diffuse Intrinsic Pontine Glioma.
What interventions are being tested in trial NCT03387020?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Everolimus (DRUG), Ribociclib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT03387020?
This trial is sponsored by Pediatric Brain Tumor Consortium, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03387020 being conducted?
This trial has 12 study locations across California, Colorado, District of Columbia, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Glioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
RECRUITING · Phase 1
-
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
RECRUITING · Phase 1
-
Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults
RECRUITING · Phase 1
-
Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial
RECRUITING · Phase 1
-
BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.